Checkpoint Capital L.P. Protagonist Therapeutics, Inc Transaction History
Checkpoint Capital L.P.
- $202 Billion
- Q3 2024
A detailed history of Checkpoint Capital L.P. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Checkpoint Capital L.P. holds 240,000 shares of PTGX stock, worth $11.2 Million. This represents 5.36% of its overall portfolio holdings.
Number of Shares
240,000
Previous 355,000
32.39%
Holding current value
$11.2 Million
Previous $12.3 Billion
12.2%
% of portfolio
5.36%
Previous 7.42%
Shares
4 transactions
Others Institutions Holding PTGX
# of Institutions
247Shares Held
56.4MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$272 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$268 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$252 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$196 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$148 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.28B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...